Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines.

Diabetes, obesity & metabolism·2026
Same author

Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.

Nature metabolism·2026
Same author

The Glucagonotropic Effect of GIP Is Negated During Insulin-Induced Hypoglycemia in Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.

Diabetes·2026
Same author

Strategies to assess PFAS emissions from a fluoropolymer manufacturing plant.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

To β or not to β: think zinc (again)!

Cell research·2026
Same author

Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men.

Journal of the Endocrine Society·2026

Related Experiment Video

Updated: Jun 21, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Interleukin-1 beta targeted therapy for type 2 diabetes.

Kathrin Maedler1, Gitanjali Dharmadhikari, Desiree M Schumann

  • 1University of Bremen, Centre for Biomolecular Interactions Bremen, Islet Biology Laboratory, 28359 Bremen, Germany. kmaedler@uni-bremen.de

Expert Opinion on Biological Therapy
|July 17, 2009
PubMed
Summary

Interleukin-1beta (IL-1beta) drives inflammation and insulin resistance, contributing to type 2 diabetes. Targeting IL-1beta shows promise for treating this metabolic disease.

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 21, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Area of Science:

  • Immunology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Interleukin-1beta (IL-1beta) is a key inflammatory regulator, implicated in numerous diseases.
  • IL-1beta is produced by macrophages and various tissues, affecting autoimmune and metabolic conditions.
  • Pancreatic islet cells are vulnerable to IL-1beta, impacting insulin production and function.

Purpose of the Study:

  • To summarize mechanisms of IL-1beta-driven inflammation and insulin resistance.
  • To highlight IL-1beta's role in the progression of type 2 diabetes.
  • To review IL-1beta as a therapeutic target for type 2 diabetes.

Main Methods:

  • Literature review of IL-1beta's role in inflammation and diabetes.
  • Analysis of clinical studies and animal experiments.
  • Examination of studies on isolated islets and IL-1beta signaling.

Main Results:

  • Macrophage-derived IL-1beta promotes inflammation and insulin resistance in obesity.
  • IL-1beta signaling contributes to the destruction and dysfunction of insulin-producing beta-cells.
  • Evidence suggests IL-1beta is a significant factor in type 2 diabetes development.

Conclusions:

  • IL-1beta is a critical mediator in the inflammatory pathways leading to insulin resistance and type 2 diabetes.
  • Targeting IL-1beta presents a potential therapeutic strategy for type 2 diabetes.
  • Further research into IL-1beta signaling is essential for developing effective treatments.